From bench to bedside: 64Cu/177Lu 1C1m-Fc anti TEM-1: mice-to-human dosimetry extrapolations for future theranostic applications

EJNMMI Research

Table 5 [⁶⁴Cu] AD to selected target organs and comparison with previously published data

[⁶⁴Cu]Cu-1C1m-Fc 3DOTA (average) AD (mGy/MBq)					AD (mGy/MBq)
Target organ	M1	M2	M3	M4	[⁶⁴Cu]Cu-DOTA-Trastuzumab [34]	[⁸⁹Zr]Zr-cmAb U36 [35]
Heart Wall	0.11	0.06	0.33	0.12	0.16
Kidneys	0.17	0.06	0.19	0.06	0.09	1
Liver	0.16	0.07	0.15	0.06	0.12	1.3
Lungs	0.04	0.06	0.05	0.07		0.79
Ovaries	0.38	0.04	0.34	0.04
Red Marrow	0.06	0.06	0.08	0.09	0.04	0.08
Spleen	0.12	0.06	0.13	0.06	0.10	0.72
Uterus	0.10	0.03	0.18	0.06
E (mSv/MBq)	0.05	0.04	0.05	0.04	0.03	0.6

The table reports average AD and the effective dose for the gender averaged human adult model obtained with the OLINDA/EXM 2.1 software for each tested dosimetry methods (M1-M4). Original data for the [⁶⁴Cu] Cu-1C1m-Fc 3DOTA are compared with previously published dosimetry from the [⁶⁴Cu]Cu-DOTA-Trastuzumab [34] and the [⁸⁹Zr]Zr-cmAb U36 [35] respectively